Oncolytics Biotech (NASDAQ:ONCY) Stock Rating Upgraded by Raymond James

Raymond James upgraded shares of Oncolytics Biotech (NASDAQ:ONCY) to a moderate buy rating in a report issued on Thursday morning,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

A number of other equities research analysts have also weighed in on ONCY. Leede Financial lowered Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research note on Wednesday. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Oncolytics Biotech in a report on Thursday.

Oncolytics Biotech Trading Down 3.0 %

Shares of NASDAQ ONCY opened at $0.98 on Thursday. The stock has a market cap of $75.53 million, a price-to-earnings ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a 1-year low of $0.84 and a 1-year high of $1.75. The stock’s 50-day moving average is $1.09 and its 200 day moving average is $1.06.

Institutional Trading of Oncolytics Biotech

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Virtu Financial LLC purchased a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech as of its most recent SEC filing. 6.82% of the stock is currently owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.